Meanwhile,DDX17 overexpression significantly down-regulates the expression of genes associated with de novo fatty acid synthesis, suggesting that DDX17 may inhibit lipid synthesis and protect against lipid accumulation in hepatocytes treated by OA/PA, which provides a potential molecular target for the treatment of metabolism-associated fatty liver disease (91). The gene discussed is DDX17; the disease is fatty liver disease.